Greenwich LifeSciences, Inc. Stock price

Equities

GLSI

US3968791083

Pharmaceuticals

Real-time Estimate Cboe BZX 11:48:09 2024-03-28 am EDT 5-day change 1st Jan Change
20.1 USD +0.53% Intraday chart for Greenwich LifeSciences, Inc. +5.02% +88.88%
Sales 2023 * - Sales 2024 * - Capitalization 257M
Net income 2023 * -8M Net income 2024 * -10M EV / Sales 2023 * -
Net cash position 2023 * - Net cash position 2024 * - EV / Sales 2024 * -
P/E ratio 2023 *
-29.4 x
P/E ratio 2024 *
-26.3 x
Employees 5
Yield 2023 *
-
Yield 2024 *
-
Free-Float 45.56%
More Fundamentals * Assessed data
Dynamic Chart
Greenwich Lifesciences Insider Bought Shares Worth $380,945, According to a Recent SEC Filing MT
Greenwich LifeSciences Secures Approval to Expand GLSI-100's Phase 3 Trial to Europe MT
Greenwich Lifesciences Flamingo-01 Manufacturing & Protocol Accepted by European Regulators CI
HC Wainwright Adjusts Greenwich LifeSciences Price Target to $36 From $38, Maintains Buy Rating MT
Greenwich LifeSciences, Inc. Provides Update on Phase III Clinical Trial, Flamingo-01 CI
Sector Update: Health Care Stocks Rise in Afternoon Trading MT
Greenwich LifeSciences Shares Surge on Planned Regulatory Filing of Breast Cancer Treatment MT
Greenwich LifeSciences Shares Rise as Company Prepares FDA Filing for Breast Cancer Immunotherapy DJ
Greenwich LifeSciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
North American Morning Briefing : Investors Await Powell's Jackson Hole Speech DJ
Greenwich LifeSciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Greenwich LifeSciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
North American Morning Briefing : Stocks to Extend -3- DJ
Greenwich Lifesciences, Inc. Confirms the Interest in Both of Itsgp2 Phase Iib Clinical Trial and Phase Iii Clinical Trial, Flamingo-01 CI
HC Wainwright Cuts Greenwich LifeSciences' Price Target to $38 From $78, Keeps Buy Rating MT
More news
1 day+0.53%
1 week+5.02%
Current month+63.40%
1 month+64.49%
3 months+84.32%
6 months+126.31%
Current year+88.88%
More quotes
1 week
19.10
Extreme 19.1001
21.44
1 month
11.20
Extreme 11.202
21.44
Current year
8.00
Extreme 8
21.44
1 year
7.58
Extreme 7.58
21.44
3 years
6.82
Extreme 6.8241
69.77
5 years
3.26
Extreme 3.262
158.07
10 years
3.26
Extreme 3.262
158.07
More quotes
Managers TitleAgeSince
Founder 49 06-08-28
Chief Executive Officer 60 10-01-31
Chairman 81 09-01-31
Members of the board TitleAgeSince
Chairman 81 09-01-31
Chief Tech/Sci/R&D Officer 74 19-08-31
Chief Executive Officer 60 10-01-31
More insiders
Date Price Change Volume
24-03-28 19.87 -0.65% 11 328
24-03-27 20 -1.57% 39,344
24-03-26 20.32 +4.47% 42,796
24-03-25 19.45 -0.87% 22,710
24-03-22 19.62 +3.70% 51,318

Delayed Quote Nasdaq, March 28, 2024 at 10:35 am EDT

More quotes
Greenwich LifeSciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of GP2, immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the human epidermal growth factor receptor 2 (HER2)/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers. GP2 will be delivered in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) to induce GP2 peptide-specific immunity. GP2 treatment is administered via an intradermal injection by mixing GP2 peptide and GM-CSF at the time of administration. The Company's Cancer immunotherapy seeks to stimulate an individual's immune system to selectively attack cancer cells while not affecting normal cells or to deliver certain immune system components to inhibit the spread of cancer.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
20 USD
Average target price
36 USD
Spread / Average Target
+80.00%
Consensus
  1. Stock
  2. Equities
  3. Stock Greenwich LifeSciences, Inc. - Nasdaq